Preclinical and Clinical Development of Human Placental Hematopoietic Stem Cell Derived NK Cells (CYNK001) for the Treatment of COVID-19

Time: 4:20 pm
day: Day Two


• Celularity has developed a novel proprietary GMP procedure that enables the scalable production of an off-the-shelf, allogeneic NK cell therapy (CYNK-001)
• Combining pathogenic mechanism of coronavirus, existing and validated research results, we hypothesize adoptive CYNK001 therapy may provide the antiviral activities thereby serve as effective solutions for COVID-19 patients
• Discuss the initial findings from our clinical investigation and continuous development of CYNK-001 for infectious diseases